Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 9/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | TK1 | P04183 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17377658 | 0.87 | KIF11 (0.47) | TK2TDP1KIF11TK1L3MBTL1 | |
| SCHEMBL17381363 | 0.84 | TDP1 (0.41) | TK2TDP1KIF11TK1L3MBTL1 | |
| SCHEMBL1885698 | 0.80 | LTB4R (0.47) | TK2KIF11TK1 | |
| SCHEMBL1887342 | 0.80 | LTB4R (0.47) | TK2KIF11TK1 | |
| SCHEMBL1885700 | 0.78 | LTB4R (0.48) | TK2KIF11TK1CYP2C9TSHR | |
| SCHEMBL1881877 | 0.78 | LTB4R (0.48) | TK2KIF11TK1CYP2C9TSHR | |
| SCHEMBL20032509 | 0.78 | LTB4R (0.48) | TK2KIF11TK1CYP2C9TSHR | |
| SCHEMBL1887343 | 0.78 | LTB4R (0.48) | TK2KIF11TK1CYP2C9TSHR | |
| SCHEMBL8972396 | 0.78 | KIF11 (0.47) | TK2KIF11TK1CYP2C9ALOX15 | |
| SCHEMBL31697420 | 0.77 | LMNA (0.48) | TK2KIF11TK1CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2195310-B1 | LUMINESCENT LANTHANIDE (III) CHELATES, CHELATING AGENTS AND CONJUGATES DERIVED THEREOF | WALLAC OY (FI) | 2016-06-01 | — | — | EP | disclosed |
| US-8221719-B2 | Luminescent lanthanide (III) chelates, chelating agents and conjugates derived thereof | WALLAC OY (FI) | 2012-07-17 | — | — | US | disclosed |
| US-20100204442-A1 | Luminescent lanthanide (III) chelates, chelating agents and conjugates derived thereof | WALLAC OY (FI) | 2010-08-12 | — | — | US | disclosed |
| EP-2195310-A1 | LUMINESCENT LANTHANIDE (III) CHELATES, CHELATING AGENTS AND CONJUGATES DERIVED THEREOF | Wallac OY (FI) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009030819-A1 | LUMINESCENT LANTHANIDE (III) CHELATES, CHELATING AGENTS AND CONJUGATES DERIVED THEREOF | WALLAC OY (FI) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204442-A1 | Luminescent lanthanide (III) chelates, chelating agents and conjugates derived thereof | LNPEP, SLC39A3, LAP3 | TK2 1096/4885TDP1 1162/4885KIF11 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.